Author/Editor		Čufer, Tanja; Borštnar, Simona
Title		Nevtropenija ob intenzivnem citostatskem zdravljenju s podporo dejavnikov rasti pri lokalno napredovalem raku dojk
Translated title		Neutropenia in patients treated with intensive chemotherapy and growth factors in locally advanced breast cancer
Type		članek
Source		Med Razgl
Vol. and No.		Letnik 35, št. Suppl 7
Publication year		1996
Volume		str. 131-41
Language		slo
Abstract		At the Institute of Oncology in Ljubijana 22 patients were included in a multicentric study of the effectiveness of intensive chemotherapy in locally advanced breast cancer. The aim of the present analysis was to determine the incidence and grade of neutropenias as well as the complications, such as infections, the need for hospitalization and change of antibiotics in the sub-sets of patients treated either with intensive chemotherapy and haematopoetic growth factors (EC + G-CSF group) or standard chemotherapy (CEF group). We also analyzed the dose intensity of cytostatics received by both groups of patients. In the EC + G-CSF group, neutropenias under 1.0 X 109/I were detected in only 18 % of cycles, whereas in the CEF group, they were detected in 42 "/o of cycles. In the group of patients who received supportive therapy with growth factors, the values of neutrophils always reached a normal level until the next treatment cycle, which was not the case in the other group of patients. In the EC + G-CSF group, there were fewer complications. No episode of temperature higher than 38 oC was found, none of the patients was hospitalized and only one had to have the antibiotic changed. On the other hand, in patients treated with standard chemotherapy, febrile neutropenia occurred three times (5.6 % of cycles) and hospitalization and change of antibiotics were also required three times. Among other side effects, only thrombocytopenia and stomatitis were slightly more frequent in the EC + G-CSF group. Although the pianned doses of cytostatics in the intensive treatment wing were almost twice as high as standard ones, a much higher percentage of planned dose was administered in this patients than in the patients treated with standard chemotherapy (94 a/o vs. 83 %). It may be concluded that the support of growth factors allows us to treat breast cancer patients with higher doses of ... Abstract truncated at 2000 characters.
Descriptors		BREAST NEOPLASMS ANTINEOPLASTIC AGENTS GROWTH SUBSTANCES NEUTROPENIA